**Biography**

**Prof Andrew Gennery**

Prof Andrew Gennery is a Professor in Paediatric Immunology and Haematopoietic Stem Cell Transplantation at the University of Newcastle upon Tyne and an Honorary Consultant for the Northern Supra-Regional Bone Marrow Transplant Unit for SCID and related disorders at the Great North Children's Hospital, Newcastle upon Tyne. He spent a year of post-doctoral studies working with Anne Durandy and Alain Fischer at the Necker Hospital in Paris, where he was involved in the discovery of Cytidine Deaminase, one of the first genes identified in class switch recombination and somatic hypermutation.

His research interests include immunoreconstitution following haematopoietic stem cell transplant for primary immunodeficiency, long-term outcomes of transplantation for primary immunodeficiency (particularly Chronic Granulomatous Disease and Severe Combined Immunodeficiency), DNA repair disorders and their appropriate treatment, and Di George Syndrome. More recently, he has adapted new methods of T cell depletion for patients with primary immunodeficiency and established extracorporeal photopheresis for treating children with graft-versus-host disease. He has discovered important mechanistic insights into the action of extracorporeal photopheresis and is exploring the use of defibrotide for treating non-VOD endothelial cell activation disorders post-HSCT.

Prof Gennery is a member of ESID and EBMT and has recently chaired the ESID/EBMT Inborn Errors Working Party group, the ESID Clinical Working Party, and the ERN-RITA Guidelines Working Party. He served as Co-chair of the CIBMTR Primary Immune Deficiencies, Inborn Errors of Metabolism, and other NMMD Working Committee until February 2024. He has published over 420 papers on primary immunodeficiency, co-authored significant multi-centre publications on outcomes of children with rare primary immunodeficiencies following HSCT and contributed to chapters in several major textbooks.

He has co-authored national guidelines for the use of irradiated blood products in patients with primary immunodeficiency in the UK, guidelines on managing children with 22q11 deletion syndrome, and guidelines for the use of extracorporeal photopheresis for treating acute graft-versus-host disease. He has also written international guidelines for treating patients with DNA repair disorders and CD40 ligand deficiency. He is the clinical lead for the SCID Newborn Screening pilot in England.

He sits on the Scientific Advisory Board for the Chronic Granulomatous Disorder Society, The Hyper IgM Foundation, and the Job's Syndrome Foundation.